The oncogenic mechanisms and therapeutic targets of RCC have been studied extensively and several genes, including VHL, PBRM1, BAP1, and SETD2, were successfully identified as being critical in the development and treatment of RCC [28]. This evidence concerns the gene SETD2 and renal cell carcinoma.